Who is sponsoring NCT05672134?

NCT05672134 is sponsored by Amsterdam UMC, location VUmc.

What drugs are being tested in NCT05672134?

Interventions in NCT05672134: Iohexol measurement, Geranylgeranylacetone (GGA), Echocardiography, 6-minute walking distance test, EndoPAT, Para-amino Hippuric Acid test, Electrocardiogram.

What condition does NCT05672134 study?

NCT05672134 studies Heart Failure With Preserved Ejection Fraction.

Is NCT05672134 still recruiting?

NCT05672134 is currently completed. Last updated 1 April 2025.

Last reviewed 2025-04-01 · How we verify

NCT05672134: GLADIATOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction

Completed Phase 2 Last updated 1 April 2025

What this trial tests

Phase 2 trial testing Iohexol measurement in Heart Failure With Preserved Ejection Fraction in 43 participants. Completed in 30 August 2024.

Timeline

26 April 2023

Primary endpoint
30 August 2024

30 August 2024

Quick facts

Lead sponsor	Amsterdam UMC, location VUmc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	43
Start date	26 April 2023
Primary completion	30 August 2024
Estimated completion	30 August 2024
Sites	1 location across Netherlands

Drugs / interventions tested

Iohexol measurement
Geranylgeranylacetone (GGA) — full drug profile →
Echocardiography
6-minute walking distance test
EndoPAT
Para-amino Hippuric Acid test
Electrocardiogram

Conditions studied

Heart Failure With Preserved Ejection Fraction — all drugs for Heart Failure With Preserved Ejection Fraction →

Sponsor

Amsterdam UMC, location VUmc — full company profile →

Who can join

50 and older, any sex, with Heart Failure With Preserved Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this double-blind randomized, placebo-controlled cross-over trial is to evaluate the effectiveness of GerenylGeranylAcetone (GGA) in patients with Heart Failure with a preserved ejection fraction. The main questions it aims to answer are: * What is the effect of GGA on diastolic function? * What is the effect of GGA on endothelial function? Main study tasks: * Participants will be treated with either GGA or placebo for 13 weeks. After this they will have a break (wash-out) period for 6 weeks and then cross over to the other study arm. * Cardiac function will be measured using echocardiogram in all participants * Renal measurements and endothelial measurements will be performed on the participants. * Participants will perform a 5 minute walking distance test for functional capacity. * Participants will fill out questionnaires to score signs \& symptoms. Researchers will compare the patients to themselves to see if the drug improves diastolic- and endothelial function.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial.
Nassiri S, Voordes GHD, van Heerebeek L, van Raalte DH, et al · · 2025 · cited 2× · PMID 40719441 · DOI 10.1002/ejhf.3711

Verify or expand the search:

Other recruiting trials for Heart Failure With Preserved Ejection Fraction

Currently open trials in the same condition.

NCT06833138 — Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillati · NA · recruiting
NCT06937827 — Transitions of Care Clinic (TOCC) · NA · recruiting
NCT07037459 — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity · Phase 3 · recruiting
NCT06702501 — The PeriCut Catheter System Early Feasibility Study (REIMAGINE-HFpEF) · NA · recruiting
NCT06616974 — A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction · Phase 2 · recruiting

Other Amsterdam UMC, location VUmc trials

Trials by the same sponsor.

NCT07470697 — Deep Relaxation Using Virtual Reality Intervention Before Surgery for Healthcare Professionals Working in the Operating · NA · not yet recruiting
NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting
NCT07155681 — Evaluating Healthcare Professionals' Satisfaction and Stress Mitigation Using Virtual Reality Intervention in Surgical W · NA · not yet recruiting
NCT06416345 — Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care · NA · recruiting
NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05672134 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amsterdam UMC, location VUmc
Last refreshed: 1 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05672134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing